DERM · Insider Trading
Journey Medical Corporation Common Stock
Every open-market purchase and sale reported by DERM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | Justin Adam Smith | Director | A | +50,000 | — |
| 2026-07-02 | Miranda Jayne Toledano | Director | A | +50,000 | — |
| 2026-07-02 | Neil Herskowitz | Director | A | +50,000 | — |
| 2026-06-29 | Miranda Jayne Toledano | Director | A | +10,000 | — |
| 2026-06-26 | Justin Adam Smith | Director | A | +10,000 | — |
| 2026-06-26 | Michael Cooper Pearce | Director | A | +10,000 | — |
| 2026-06-26 | Lindsay A Md Rosenwald | Director | A | +10,000 | — |
| 2026-06-26 | Neil Herskowitz | Director | A | +10,000 | — |
| 2026-04-24 | Joseph Benesch | CFO | A | +28,907 | — |
| 2026-04-24 | Ramsey Alloush | Chief Operating Officer | A | +46,863 | — |
| 2026-04-24 | Claude Maraoui | President & CEO | A | +49,277 | — |
| 2025-08-26 | Claude Maraoui | President & CEO | MIXED | +1,239,123 | −$1 |
| 2025-08-07 | Michael Cooper Pearce | Director | A | +20,000 | — |
| 2025-08-07 | Miranda Jayne Toledano | Director | A | +20,000 | — |
| 2025-08-07 | Justin Adam Smith | Director | A | +20,000 | — |
| 2025-08-07 | Lindsay A Md Rosenwald | Director | A | +50,000 | — |
| 2025-08-07 | Neil Herskowitz | Director | A | +20,000 | — |
| 2025-07-07 | Lindsay A Md Rosenwald | Director | A | +7,173 | — |
| 2025-07-07 | Michael Cooper Pearce | Director | A | +7,173 | — |
| 2025-07-07 | Miranda Jayne Toledano | Director | A | +7,173 | — |
| 2025-07-07 | Justin Adam Smith | Director | A | +7,173 | — |
| 2025-07-07 | Neil Herskowitz | Director | A | +7,173 | — |
| 2025-06-20 | Ramsey Alloush | Chief Operating Officer | A | +46,863 | — |
| 2025-06-20 | Claude Maraoui | President & CEO | A | +49,277 | — |
| 2025-06-20 | Joseph Benesch | CFO | A | +28,907 | — |
| 2025-05-05 | Joseph Benesch | CFO | Sell | −2,409 | −$16.48K |
| 2025-05-05 | Claude Maraoui | President & CEO | Sell | −4,834 | −$33.06K |
| 2025-05-05 | Ramsey Alloush | COO | Sell | −2,857 | −$19.54K |
| 2025-04-16 | Claude Maraoui | President & CEO | A | +350,000 | — |
| 2025-04-16 | Joseph Benesch | CFO | A | +160,000 | — |
| 2025-03-11 | Claude Maraoui | President & CEO | Sell | −49,271 | −$246.85K |
| 2025-03-10 | Claude Maraoui | President & CEO | Sell | −40,456 | −$203.45K |
| 2025-03-05 | Claude Maraoui | President & CEO | Sell | −70,556 | −$360.76K |
| 2025-02-24 | Joseph Benesch | CFO | Sell | −1,365 | −$7.08K |
| 2024-08-01 | Joseph Benesch | CFO | Sell | −9,324 | −$51.00K |
| 2024-07-23 | Joseph Benesch | CFO | Sell | −4,055 | −$21.90K |
| 2024-07-23 | Michael Cooper Pearce | Director | A | +30,000 | — |
| 2024-07-10 | Justin Adam Smith | Director | A | +9,728 | — |
| 2024-07-10 | Lindsay A Md Rosenwald | Director | A | +9,728 | — |
| 2024-07-10 | Neil Herskowitz | Director | A | +9,728 | — |
| 2024-07-10 | Miranda Jayne Toledano | Director | A | +9,728 | — |
| 2024-05-31 | Fortress Biotech, Inc. | 10%+ Owner | J | −250,000 | — |
| 2024-03-27 | Lindsay A Md Rosenwald | Director | Buy | +10,000 | +$30.40K |
| 2024-03-25 | Claude Maraoui | President & CEO | Buy | +10,000 | +$34.79K |
| 2024-03-25 | Lindsay A Md Rosenwald | Director | Buy | +20,000 | +$68.00K |
| 2024-03-25 | Justin Adam Smith | Director | Buy | +30,000 | +$104.10K |
| 2024-02-23 | Joseph Benesch | Interim CFO | Sell | −2,450 | −$9.19K |
| 2023-12-08 | Jeffrey Paley | Director | Sell | −2,500 | −$8.77K |
| 2023-11-29 | Jeffrey Paley | Director | Sell | −1,745 | −$9.11K |
| 2023-10-17 | Justin Adam Smith | Director | Buy | +33,000 | +$98.34K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Claude Maraoui | President & CEO | 2,435,990 | $12.25M |
| Ramsey Alloush | Chief Operating Officer | 598,543 | $3.01M |
| Lindsay A Md Rosenwald | Director | 397,616 | $2.00M |
| Joseph Benesch | CFO | 261,371 | $1.31M |
| Justin Adam Smith | Director | 231,618 | $1.17M |
| Neil Herskowitz | Director | 168,618 | $848.15K |
| Miranda Jayne Toledano | Director | 168,618 | $848.15K |
| Michael Cooper Pearce | Director | 67,173 | $337.88K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DERM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.